Neuralstem, Inc. CUR
announced that it has granted licenses to intellectual property surrounding
its spinal cord delivery platform, floating cannula, and method for delivering
therapeutic agents to the spinal cord to Cedars-Sinai Medical Center, a
non-profit academic medical center located in Los Angeles, CA. The license
agreements grant Cedars-Sinai Medical Center the non-exclusive right to use
the licensed intellectual property in academic research. This is the second
group of licenses announced by Neuralstem for these technologies. The
financial terms of the agreement were not disclosed. Neuralstem holds the
exclusive worldwide licenses to the platform and cannula technologies.
The platform and cannula have been used since 2010 in a Phase I ALS trial,
sponsored by Neuralstem and recently completed at Emory University, covering
the delivery of Neuralstem's NSI-566 neural stem cells into the spinal cords
of patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Neuralstem recently received FDA approval to commence a Phase I trial in
chronic spinal cord injury using the platform and cannula technologies.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in